Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06973291 · ClinicalTrials.gov registry record · Phase 3

A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

A Phase 3 study of Plaque Psoriasis, sponsored by Takeda.

Active
Registry status
Phase 3
Development phase
606
Enrollment target
20
Study locations

NCT06973291 is a Phase 3 study of Plaque Psoriasis that is active but no longer recruiting, run by Takeda. The registered enrollment target is 606 participants, above the 402-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (51% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06973291, a Phase 3 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Takeda.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
606 participants
Enrollment target
20
Study locations

Study Summary

The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque psoriasis. Participants will take one tablet daily of either zasocitinib or a matching placebo, along with one capsule daily of either over-encapsulated deucravacitinib or a matching placebo, for a duration of 16 weeks. Participants will be in the study for up to 25 weeks, which includes screening period of up to 35 days, a 16-week treatment period, and a 4-week safety follow-up period.

Conditions Studied

Plaque Psoriasis

Interventions

  • DRUG Deucravacitinib
  • DRUG Zasocitinib
  • DRUG Placebo to match zasocitinib
  • DRUG Placebo to match deucravacitinib

Study Locations (20)

California

  • Zenith Research, Inc. - Beverly Hills
  • First OC Dermatology Research Inc. - Fountain Valley
  • UNISON Clinical Trials (Shahram Jacobs md inc.) - Sherman Oaks

Florida

  • Direct Helpers Research Center - Hialeah
  • San Marcus Research Clinic Inc - Miami Lakes
  • Advanced Clinical Research Institute - Tampa

Arkansas

  • Johnson Dermatology - Fort Smith
  • Burke Pharmaceutical Research - Hot Springs

Connecticut

  • Central Connecticut Dermatology, PLLC - Cromwell
  • Yale University School of Medicine - New Haven

Illinois

  • Arlington Dermatology - Rolling Meadows
  • Endeavor Health Clinical Trials - Skokie

Indiana

  • Dawes Fretzin Clinical Research Group, LLC - Indianapolis

Maryland

  • Lawrence J Green, MD LLC - Rockville

Michigan

  • Henry Ford Health System - Detroit

Trial Details

FieldValue
Enrollment Target 606 participants
Start Date 2025-07-09
Est. Completion 2026-07-03
Phase Phase 3

Sponsor

Takeda

408 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06973291

The ClinicalTrials.gov registry entry for NCT06973291 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 606 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 402-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (51% higher). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 4 interventions - of which Deucravacitinib is the first listed.

NCT06973291 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Arkansas.

Frequently Asked Questions

What is clinical trial NCT06973291 about?

NCT06973291 is a clinical study titled "A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis". The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque psoriasis. Participants will take one tablet daily of either zasocitinib or a matching placebo, along with one capsule daily of either over-encapsula...

What is the current status of trial NCT06973291?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 606 participants. The study started on 2025-07-09. Estimated completion is 2026-07-03.

What conditions does trial NCT06973291 study?

This clinical trial studies the following conditions: Plaque Psoriasis.

What interventions are being tested in trial NCT06973291?

The interventions under investigation include: Deucravacitinib (DRUG), Zasocitinib (DRUG), Placebo to match zasocitinib (DRUG), Placebo to match deucravacitinib (DRUG).

Who is sponsoring clinical trial NCT06973291?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06973291 being conducted?

This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Plaque Psoriasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Plaque Psoriasis

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.